Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

Source :: Legal Monitor Worldwide. January 25, 2020
Publication Year :: 2020
Abstract: Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced that it has completed the required fed-fasting and dose proportionality tests of TNX-102 SL in healthy volunteers [...]

Subjects :: Fasting
Post-traumatic stress disorder -- Research -- Care and treatment
Cyclobenzaprine
Fibromyalgia
Business, international
Law

Tools